|
This summer Dr. Rahhal participated in a panel discussion at the Ophthalmology Innovation Summit at the Americas Society for Retina Specialists meeting in Vancouver. The Ophthalmology Innovation Summits unite industry, entrepreneurial and clinical leaders to collaborate on the development and commercialization of innovative drugs and devices to address unmet clinical needs. Dr. Rahhal joined Angela Macfarlane of ForSight Labs, Ron Weiss, MD, from InFocus Capital Partners and Cameron Wheeler, a Principal at Deerfield Management in a panel discussion on the 2018 financing environment. The panel was moderated by William J. Link, PhD of Versant Ventures. Dr. Rahhal later joined OIS Podcast Host Tom Salemi, Greg Grunberg, MD, and OIS Contributors Richard Mark Kirkner and Bérénice Magistretti about some of the key takeaways for investors, physicians and patients.We're looking forward to attending the next OIS in Chicago October 25 at the American Academy of Ophthalmology meeting.
0 Comments
ExSight portfolio company LensGen announced additional financing and patent grants. LensGen is developing the world's first modular, fluid-optic, curvature changing intraocular lens ("IOL"). LensGen “achieved a key clinical performance milestone which triggered the release of $11 million in funding as part of the Series A Financing.” HOYA, the lead investor, also exercised an option to invest an additional $4.4M under the terms of the Series A financing. In the same period, the US Patent Office granted LensGen two new patents that give the company comprehensive protection of its technology. The additional funding will take the Company closer to bringing the Juvene platform to market.
We're very proud to be a part of the Company's journey. Congratulations to the LensGen team! Full Press Release |
AuthorExSight Ventures Archives
December 2019
Categories |
RSS Feed